Lighting Science (LSCG) 10-Q 2015 Q1 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2015
OR
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                 to                

Commission File No. 000-20354

LIGHTING SCIENCE GROUP CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	23-2596710
(State or other jurisdiction of incorporation)	(IRS Employer Identification No.)
1830 Penn Street, Melbourne, FL	32901
(Address of principal executive offices)	(Zip Code)

(321) 779-5520 

(Registrant’s telephone number, including area code)

Indicate by check mark whether registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ☒   Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  ☒   Yes ☐   No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company 

 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐  Yes ☒ No

The number of shares outstanding of the registrant’s Common Stock, par value $0.001 per share, as of May 13, 2015, was 212,004,390 shares.

LIGHTING SCIENCE GROUP CORPORATION
AND SUBSIDIARIES
FORM 10-Q
For the Quarter Ended March 31, 2015

Table of Contents

	Page
PART I
Item 1. Financial Statements (Unaudited)	1
Condensed Consolidated Balance Sheets as of March 31, 2015 and December 31, 2014	1
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2015 and 2014	2
Condensed Consolidated Statement of Stockholders’ Deficit for the Three Months Ended March 31, 2015	3
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2015 and 2014	4
Notes to the Condensed Consolidated Financial Statements (Unaudited)	5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	15
Item 4. Controls And Procedures	24
PART II
Item 6. Exhibits	24
SIGNATURES	25

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

LIGHTING SCIENCE GROUP CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	March 31,			December 31,
	2015			2014
Assets
Current assets:
Cash and cash equivalents	$	549,383		$	1,609,297
Restricted cash		3,000,000			3,000,000
Accounts receivable, net		10,145,554			10,417,985
Inventories		28,093,828			22,726,162
Prepaid expenses		1,800,595			2,936,837
Other current assets		1,794,591			1,610,544
Total current assets		45,383,951			42,300,825
Property and equipment, net		2,166,389			2,650,115
Intangible assets, net		2,644,862			2,572,479
Pegasus Commitment		339,200			720,000
Debt issuance costs, less current portion		2,958,120			3,230,446
Other long-term assets		115,195			118,467
Total assets	$	53,607,717		$	51,592,332
Liabilities and Stockholders’ Deficit
Current liabilities:
Lines of credit	$	11,324,585		$	6,368,793
Current portion of long-term debt		67,749			58,574
Accounts payable		10,301,294			19,364,552
Provision for losses on non-cancelable purchase commitments		717,714			540,227
Accrued expenses		8,993,538			9,924,316
Total current liabilities		31,404,880			36,256,462
Note payable		28,163,286			27,813,061
Long-term debt, less current portion		16,524			35,272
Liabilities under derivative contracts		13,421,201			5,636,944
Total other liabilities		41,601,011			33,485,277
Total liabilities		73,005,891			69,741,739
Series H Redeemable Convertible Preferred Stock, $.001 par value, authorized 135,000 shares, 113,609shares issued and outstanding as of March 31, 2015 and December 31, 2014		227,220,149			227,220,149
Series I Redeemable Convertible Preferred Stock, $.001 par value, authorized 90,000 shares, 62,365shares issued and outstanding as of March 31, 2015 and December 31, 2014		124,736,627			124,736,627
Series J Redeemable Convertible Preferred Stock, $.001 par value, authorized 70,000 shares, 70,000and 58,475 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively		140,000,000			116,950,000
		491,956,776			468,906,776
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $.001 par value, authorized 25,000,000 shares, 113,609 shares of Series H,62,365 shares of Series I and 70,000 shares of Series J issued and outstanding as of March 31,2015 and 113,609 shares of Series H, 62,365 shares of Series I and 58,475 shares of Series Jissued and outstanding as of December 31, 2014
Common stock, $.001 par value, authorized 975,000,000 shares, 214,488,468 and 212,452,636shares issued as of March 31, 2015 and December 31, 2014, respectively		214,489			212,453
Additional paid-in capital		309,430,336			320,175,440
Accumulated deficit		(813,929,663	)		(800,328,573	)
Accumulated other comprehensive loss		(3,312,612	)		(3,358,003	)
Treasury stock, 2,505,000 shares as of March 31, 2015 and December 31, 2014, at cost		(3,757,500	)		(3,757,500	)
Total stockholders’ deficit		(511,354,950	)		(487,056,183	)
Total liabilities and stockholders’ deficit	$	53,607,717		$	51,592,332

The accompanying notes are an integral part of the condensed consolidated financial statements.

1

LIGHTING SCIENCE GROUP CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

	For the Three Months Ended March 31,
	2015			2014
Revenue	$	19,371,545		$	25,925,841
Cost of goods sold (exclusive of depreciation shown below)		16,441,297			23,462,953
Gross profit		2,930,248			2,462,888
Operating expense:
Selling, distribution and administrative (includes related party expenses of $0and $609,000 for the three months ended March 31, 2015 and 2014, respectively)		5,095,581			8,966,338
Research and development		1,181,313			1,544,024
Restructuring expense		83,704			205,052
Depreciation and amortization		506,072			1,076,010
Total operating expenses		6,866,670			11,791,424
Loss from operations		(3,936,422	)		(9,328,536	)
Other income (expense):
Interest income		-			411
Interest expense		(1,462,360	)		(1,343,225	)
Related party interest expense		(138,300	)		-
Increase in fair value of liabilities under derivative contracts		(8,100,772	)		(29,479,538	)
Other income, net		36,764			56,925
Total other expense		(9,664,668	)		(30,765,427	)
Loss before income tax expense		(13,601,090	)		(40,093,963	)
Income tax expense		-			-
Net loss		(13,601,090	)		(40,093,963	)
Foreign currency translation gain		45,391			172,604
Comprehensive loss	$	(13,555,699	)	$	(39,921,359	)
Basic and diluted net loss per weighted average common share attributableto controlling shareholders	$	(0.07	)	$	(0.33	)
Basic and diluted net loss per weighted average common share attributableto noncontrolling shareholders	$	(0.07	)	$	(0.35	)
Basic and diluted weighted average number of common shares outstanding attributableto controlling shareholders		287,758,558			170,973,536
Basic and diluted weighted average number of common shares outstanding attributableto noncontrolling shareholders		97,668,138			36,854,212

The accompanying notes are an integral part of the condensed consolidated financial statements. 

2

LIGHTING SCIENCE GROUP CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

(Unaudited)

											Accumulated
					Additional						Other
	Common Stock				Paid-in			Accumulated			Comprehensive			Treasury
	Shares		Amount		Capital			Deficit			Loss			Stock			Total
Balance December 31, 2014		212,452,636	$	212,453	$	320,175,440		$	(800,328,573	)	$	(3,358,003	)	$	(3,757,500	)	$	(487,056,183	)
Issuance of restricted stock and options for directors' compensation		2,033,905		2,034		9,067			-			-			-			11,101
Stock based compensation expense		-		-		905,396			-			-			-			905,396
Stock issued under equity compensation plans		1,927		2		250			-			-			-			252
Series J Warrants issued		-		-		3,638,443			-			-			-			3,638,443
Deemed dividends on Series J Redeemable Convertible Preferred Stock		-		-		(15,298,260	)		-			-			-			(15,298,260	)
Net loss		-		-		-			(13,601,090	)		-			-			(13,601,090	)
Foreign currency translation adjustment		-		-		-			-			45,391			-			45,391
Balance March 31, 2015		214,488,468	$	214,489	$	309,430,336		$	(813,929,663	)	$	(3,312,612	)	$	(3,757,500	)	$	(511,354,950	)

The accompanying notes are an integral part of the condensed consolidated financial statements.

3

LIGHTING SCIENCE GROUP CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Three Months Ended March 31,
	2015			2014
Cash flows from operating activities:
Net loss	$	(13,601,090	)	$	(40,093,963	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		506,072			1,076,010
Issuance of restricted stock and stock options for directors' compensation		11,101			73,348
Stock based compensation expense		905,396			916,657
Non-cash sales incentive		64,285			90,861
Allowance for doubtful accounts receivable		35,725			25,768
Write-down of inventory		94,595			689,637
Provision for losses on non-cancelable purchase commitments		176,857			(112,527	)
Increase (decrease) in fair value of derivative contracts		8,100,772			29,479,538
Amortization of debt issuance costs		333,847			188,011
Medley discount accretion		194,768			84,399
Interest accrued on Medley Term Loan		155,457			69,501
Loss on disposal of assets		-			42,690
Changes in operating assets and liabilities:
Accounts receivable		262,155			(9,459,143	)
Inventories		(5,466,179	)		(3,396,648	)
Prepaid expenses		1,136,362			(402,433	)
Other current and long-term assets		(130,079	)		(1,914,922	)
Accounts payable		(9,052,644	)		(2,005,522	)
Accrued expenses and other liabilities		(920,378	)		(146,805	)
Net cash used in operating activities		(17,192,978	)		(24,795,543	)
Cash flows from investing activities:
Purchases of property and equipment		(2,835	)		(153,420	)
Capitalized patents		(91,889	)		(222,175	)
Proceeds from sale of property and equipment		-			370,100
Net cash used in investing activities		(94,724	)		(5,495	)
Cash flows from financing activities:
Net proceeds (payments) from draws on lines of credit and other short-term borrowings		4,955,792			(30,198,924	)
Proceeds from long-term borrowings		-			29,775,000
Payment of short and long-term debt		(9,573	)		(1,316	)
Debt issuance costs		(112,217	)		-
Decrease in restricted cash related to line of credit		-			2,000,000
Proceeds from issuance of common stock under equity compensation plans		252			1,962
Proceeds from issuance of Series J Redeemable Convertible Preferred Securities		11,525,000			17,475,000
Fees incurred on issuance of preferred stock		(134,817	)		(217,880	)
Net cash provided by financing activities		16,224,437			18,833,842
Effect of exchange rate changes on cash		3,351			84,859
Net decrease in cash		(1,059,914	)		(5,882,337	)
Cash and cash equivalents balance at beginning of period		1,609,297			11,195,412
Cash and cash equivalents balance at end of period	$	549,383		$	5,313,075
Supplemental disclosures:
Interest paid during the period	$	1,380,181		$	1,059,079
Non-cash investing and financing activities:
Deemed dividends on Series J Redeemable Convertible Preferred Stock	$	(15,298,260	)	$	(30,198,619	)
Deemed dividends on issuance of Pegasus Guaranty Warrants	$	-		$	(570,574	)

The accompanying notes are an integral part of the condensed consolidated financial statements.

4

LIGHTING SCIENCE GROUP CORPORATION AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Note 1. Description of Business and Basis of Presentation

Overview

Lighting Science Group Corporation (the “Company”) was incorporated in Delaware in 1988 and designs, develops, manufactures and markets general illumination products that exclusively use light emitting diodes (“LEDs”) as their light source. The Company’s product portfolio includes LED-based retrofit lamps (replacement bulbs) that can be used in existing light fixtures and sockets as well as purpose built LED-based luminaires (light fixtures) for many common indoor and outdoor residential, commercial, industrial and public infrastructure lighting applications. The Company assembles and manufactures products primarily through its contract manufacturers in Asia.

Basis of Financial Statement Presentation

The accompanying unaudited condensed consolidated financial statements are presented pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) in accordance with the disclosure requirements for the quarterly report on Form 10-Q and therefore do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to fairly state the results for the interim periods presented. The condensed consolidated balance sheet as of December 31, 2014 is derived from the Company’s audited financial statements. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results of the Company that may be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2014 and notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2015.

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the accompanying consolidated financial statements.

Note 2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. The Company’s actual results could differ from these estimates.

Restricted Cash

As of March 31, 2015 and December 31, 2014, as required by the Company’s five-year term loan (as amended from time to time, the “Medley Term Loan”)with Medley Capital Corporation (“Medley”), the Company maintained a minimum restricted cash balance of $3.0 million to collateralize theMedley Term Loan. Changes in the restricted cash balance are reflected as a financing activity in the consolidated statement of cash flows.

Accounts Receivable

The Company records accounts receivable at the invoiced amount when its products are shipped to customers or when specific milestone billing requirements are completed. The Company’s accounts receivable balance is recorded net of allowances for amounts not expected to be collected from customers. This allowance for doubtful accounts is the Company’s best estimate of probable credit losses in the Company’s existing accounts receivable. Estimates used in determining the allowance for doubtful accounts are based on historical collection experience, age of receivables and known collectability issues. The Company writes off accounts receivable when it becomes apparent, based on age or customer circumstances, that such amounts will not be collected. The Company reviews its allowance for doubtful accounts on a quarterly basis. Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. Generally, the Company does not require collateral for its accounts receivable and does not regularly charge interest on past due amounts. As of March 31, 2015 and December 31, 2014, the Company’s accounts receivable were reflected net of an allowance for doubtful accounts of $448,000 and $408,000, respectively.

5

As of March 31, 2015 and December 31, 2014, $7.2 million and $5.4 million of eligible accounts receivable were pledged as collateral for the three year asset based revolving credit facility (as amended from time to time, the “FCC ABL”) entered into on April 25, 2014 with FCC, LLC d/b/a First Capital (“First Capital”).

Revenue Recognition

The Company records revenue when its products are shipped and title passes to customers. When sales of products are subject to certain customer acceptance terms, revenue from such sales is recognized once those terms have been met. The Company also provides its customers with limited rights of return for non-conforming shipments or product warranty claims.

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09,Revenue from Contracts with Customers (“ASU 2014‑09”). ASU 2014-09 seeks to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards. ASU 2014‑09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company is currently evaluating the impact of adopting ASU 2014‑09, but the standard is not expected to have a significant effect on its consolidated financial statements.

Product Warranties

The Company generally provides a five-year limited warranty covering defective materials and workmanship of its products. Such warranty may require the Company to repair, replace or reimburse the purchaser for the purchase price of the product. The estimated costs related to warranties are accrued at the time products are sold based on various factors, including the Company’s stated warranty policies and practices, the historical frequency of claims and the cost to repair or replace its products under warranty. The warranty provision is included in accrued expenses on the condensed consolidated balance sheet. Changes in the warranty provision for the three months ended March 31, 2015 were as follows:

Warranty provision as of December 31, 2014	$	4,789,470
Additions to provision		563,109
Less warranty costs		(1,319,405	)
Warranty provision as of March 31, 2015	$	4,033,174

Fair Value Measurements

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

• Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

• Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

• Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

Fair Value of Financial Instruments

Cash and cash equivalents, accounts receivable, accounts payable, amounts due under lines of credit and other short term borrowings, accrued expenses and note payable are carried at amounts that approximate their fair value due to the short-term maturity of these instruments and/or variable, market driven interest rates.

The liabilities under derivative contracts, which represent warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), were initially recorded at fair value and subsequently reflected at their fair value at the end of each reporting period. The fair value of the warrant issued to The Home Depot, Inc. (the “THD Warrant”) in January 2011, is determined using the Monte Carlo valuation method and will be adjusted at each reporting date until the underlying shares have been earned for each year. Such adjustments will be recorded as a reduction in the related revenue (sales incentive) from The Home Depot. Once a portion of the THD Warrant vests it is recorded at its fair value at the end of each subsequent reporting period.

6

Reclassification

Certain prior period amounts in the accompanying consolidated financial statements have been reclassified to conform to the current year presentation. These reclassifications had no effect on previously reported net loss or stockholders’ deficit.

Note 3. Liquidity and Capital Resources

As shown in the condensed consolidated financial statements, the Company has experienced significant net losses as well as negative cash flows from operations since its inception, resulting in an accumulated deficit of $813.9 million and stockholders’ deficit of $511.4 million as of March 31, 2015. The Company’s cash expenditures primarily relate to procurement of inventory, payment of salaries, employee benefits and other operating costs. The Company’s primary sources of liquidity have historically been borrowings from First Capital under the FCC ABL, from Medley under the Medley Term Loan and other previous lenders, as well as sales of Common Stock and the Company’s preferred stock to, and short-term loans from, affiliates of Pegasus Capital Advisors, L.P. (“Pegasus Capital”), including Pegasus Partners IV, L.P. (“Pegasus IV”), LSGC Holdings LLC (“LSGC Holdings”), LSGC Holdings II LLC (“Holdings II”), LSGC Holdings III LLC (“Holdings III”) and PCA LSG Holdings, LLC (“PCA Holdings” and collectively with Pegasus Capital, Pegasus IV, LSGC Holdings, Holdings II, Holdings III and their affiliates, “Pegasus”). Pegasus is the Company’s controlling stockholder.

On February 19, 2014, the Company entered into an agreement with Medley (as amended from time to time the “Medley Loan Agreement”) pursuant to which the Company obtained the five-year, $30.5 million Medley Term Loan.

On April 25, 2014, the Company entered into the FCC ABL, a three-year revolving credit facility with First Capital. As of March 31, 2015, the Company had $11.3 million outstanding under the FCC ABL and additional borrowing capacity of $4.5 million. As of March 31, 2015, the Company had cash and cash equivalents of $549,000 and an additional $3.0 million in restricted cash subject to a cash collateral dominion agreement pursuant to the Medley Term Loan. The FCC ABL provides the Company with a maximum borrowing capacity of $22.5 million, which capacity is based on a formula of eligible accounts receivable and inventory. The Company is required to comply with certain specified EBITDA requirements, maintain a specified lamp sourcing percentage and comply with maximum capital expenditure limits.

Commencing on September 25, 2015, RW LSG Holdings LLC (“Riverwood”) and Pegasus will have the right to cause the Company to redeem their shares of Series H Convertible Preferred Stock (“Series H Preferred Stock”) and Series I Convertible Preferred Stock (“Series I Preferred Stock”), respectively. If either Riverwood or Pegasus elects to cause the Company to redeem its shares of Series H Preferred Stock or Series I Preferred Stock, all other holders of the applicable series will have the right to redeem their shares of Preferred Stock. In addition, commencing 10 business days after September 25, 2015, each of Portman Limited (“Portman”) and affiliates of Zouk Holdings Limited, jointly, has a contractual right to require the Company to redeem its shares of Series H Preferred Stock. The Company is also required to redeem the outstanding shares of its Series J Convertible Preferred Stock (“Series J Preferred Stock” and collectively with Series H Preferred Stock and Series I Preferred Stock, the “Preferred Stock”) (a) subject to certain limited exceptions, immediately prior to the redemption of the Series H Preferred Stock, Series I Preferred Stock or any other security that ranks junior to the Series J Preferred Stock and (b) on November 14, 2019, at the election of the holders of Series J Preferred Stock (a “Special Redemption”). Each holder of the Company’s preferred stock would also have the right to require it to redeem such shares upon the uncured material breach of the Company’s obligations under its outstanding indebtedness or the uncured material breach of the terms of the certificates of designation governing its preferred stock. In total, the maximum payment obligation of the Company in the event of a redemption of all the Series H, I and J Preferred Stock is $492.0 million. Finally, the Company would be required to pay its outstanding obligations under the Medley Term Loan and the FCC ABL prior to any such redemption of shares of Preferred Stock. As of March 31, 2015, the aggregate borrowings outstanding under these loan facilities was $39.5 million.

Any redemption of the Preferred Stock would be limited to funds legally available therefor under Delaware law. The certificates of designation governing the Company's preferred stock provide that if there is not a sufficient amount of cash or surplus available to pay for a redemption of Preferred Stock, then the redemption shall be paid out of the remaining assets of the Company. In addition, the Amended and Restated Certificate of Designation of Series J Preferred Stock provides that the Company is not permitted or required to redeem any shares of Series J Preferred Stock for so long as such redemption would result in an event of default under the Company’s credit facilities. If the Company does not have sufficient capital available to redeem the Series J Preferred Stock in connection with a Special Redemption of the Series J Preferred Stock, the Company will be required to issue a non-interest bearing note or notes (payable 180 days after issuance) in the principal amount of the liquidation amount of any shares of Series J Preferred Stock not redeemed by the Company in connection with such Special Redemption, subject to certain limitations imposed by Delaware law governing distributions to stockholders. As of March 31, 2015, based solely on a review of the Company’s balance sheet, the Company did not have legally available funds under Delaware law to satisfy a redemption of its Preferred Stock. In addition, based solely on the Company’s projected balance sheet as of September 25, 2015, the Company does not believe that it will have legally available funds on or before September 25, 2015 to satisfy any such redemption.

7

On January 30, 2015, the Company issued an additional 11,525 units of its Series J securities (“Series J Securities”), at a purchase price of $1,000 per Series J Security for aggregate proceeds of $11.5 million. Each Series J Security consists of (i) one share of Series J Preferred Stock and (ii) a warrant to purchase 2,650 shares of the Company’s Common Stock, at an exercise price of $0.001 per share (the “Series J Warrants”). The Series J Securities were issued pursuant to a subscription agreement entered into between the Company and Holdings III.

The Company continues to face challenges in its efforts to achieve positive cash flows from operations and profitability. The Company’s ability to meet its obligations in the ordinary course of business is dependent upon establishing profitable operations, which may be supplemented by any additional funds raised through public or private financing or increased borrowing capacity. The current business plan includes a focus on increasing revenue by updating and expanding our product offerings and capitalizing on the known product needs of our existing customers, improving gross margins by significantly leveraging contract manufacturers in Asia and reducing operating costs, primarily through the restructuring initiated in 2013. In future periods, if the Company does not adequately execute upon its business plan or its assumptions or forecasts do not prove to be accurate, the Company could exhaust its available capital resources, which could require the Company to seek to raise additional capital and/or further reduce its expenditures of cash. There can be no assurance that sources of liquidity will be available in an amount or on terms that are acceptable to the Company, if at all.

Note 4. Detail of Certain Balance Sheet Accounts

Inventories

Inventories consisted of finished goods as of March 31, 2015 and December 31, 2014. As of March 31, 2015 and December 31, 2014, inventories were stated net of inventory write downs of $6.6 million and $7.9 million, respectively. The Company considered a number of factors in estimating the required inventory write downs, including (i) the focus of the business on the next generation of the Company’s products, which utilize lower cost technologies, (ii) the strategic focus on core products to meet the demands of key customers and (iii) the expected demand for the Company’s current generation of products, which is approaching the end of its lifecycle upon the introduction of the next generation of products.

Property and Equipment, Net

Property and equipment, net consisted of the following as of the dates indicated:

	March 31, 2015			December 31, 2014
Leasehold improvements	$	158,421		$	158,421
Office furniture and equipment		293,184			293,183
Computer hardware and software		7,882,067			7,876,262
Tooling, production and test equipment		4,559,918			4,559,942
Trailers		45,996			45,996
Construction-in-process		42,855			45,817
Total property and equipment		12,982,441			12,979,621
Accumulated depreciation		(10,816,052	)		(10,329,506	)
Total property and equipment, net	$	2,166,389		$	2,650,115

Depreciation related to property and equipment was $487,000 and $1.1 million for the three months ended March 31, 2015 and 2014, respectively.

8

Note 5. Intangible Assets

Intangible assets that have finite lives are amortized over their useful lives. The Company’s intangible assets as of March 31, 2015 and December 31, 2014 are detailed below:

	Cost, Less Impairment Charges		Accumulated Amortization			Net Book Value		Estimated Remaining Useful Life
March 31, 2015:
Technology and intellectual property	$	2,888,469	$	(243,607	)	$	2,644,862	2.4 to 20.0 years
December 31, 2014:
Technology and intellectual property	$	2,796,580	$	(224,101	)	$	2,572,479	2.7 to 20.0 years

Total intangible asset amortization expense was $20,000 and $14,000 for the three months ended March 31, 2015 and 2014, respectively.

Note 6. Debt Issuance Costs

The Company capitalizes its costs related to the issuance of long-term debt and amortizes these costs using the effective interest rate method over the life of the loan. Amortization of debt issuance costs and the accelerated write-off of debt issuance costs in connection with refinancing activities are recorded as a component of interest expense. As of March 31, 2015, the current portion of the debt issuance costs was $1.4 million and was included in other current assets. In connection with the FCC ABL and the Medley Term Loan, $6.0 million of debt issuance costs were capitalized, including $2.8 million related to the fair value of the guaranty of the Company’s obligations under the Medley Loan Agreement in favor of Medley (the “Pegasus Guaranty”) provided by Pegasus Capital Partners IV, L.P. and Pegasus Capital Partners V, L.P. (collectively, the “Pegasus Guarantors”). The Company amortized $334,000 and $188,000 of debt issuance costs for the three months ended March 31, 2015 and 2014, respectively.

Note 7. Lines of Credit and Note Payable

	Balance Outstanding as of
Facility	March 31, 2015		December 31, 2014
First Capital, revolving line of credit	$	11,324,585	$	6,368,793
Medley Term Loan		28,163,286		27,813,061
	$	39,487,871	$	34,181,854

First Capital

On April 25, 2014, the Company, entered into the FCC ABL, which provides the Company with a maximum borrowing capacity of $22.5 million, which capacity is based on a formula of eligible accounts receivable and inventory.As of March 31, 2015, the Company had $11.3 million outstanding under the FCC ABL and additional borrowing capacity of $4.5 million. As of March 31, 2015, eligible collateral included $7.2 million of accounts receivable and $10.0 million of inventory. Borrowings under the FCC ABL bear interest at a floating rate equal to one-month LIBOR plus 4.0% per annum. As of March 31, 2015, the interest rate on the FCC ABL was 4.17%.

On January 30, 2015, the Company entered into an amendment to the FCC ABL, which provided additional notification and consent requirements as well as updates to certain disclosure schedules to the FCC ABL agreement. In connection with this amendment FCC also agreed to amend the calculation of EBITDA for purposes of determining compliance with the fixed charge coverage ratio covenant for each of the six-month period ending March 31, 2015, the nine month period ending June 30, 2015, the twelve-month period ending September 30, 2015 and the twelve-month period ending December 31, 2015.

9

MedleyTerm Loan

On February 19, 2014, the Company entered into the Medley Term Loan, which provided the Company with a $30.5 million term loan facility. The Medley Term Loan bears interest at a floating rate equal to three-month LIBOR plus 12% per annum, and as of March 31, 2015, the interest rate on the Medley Term Loan was 12.26%. Additionally, $3.0 million of the Medley Term Loan was funded directly into a deposit account to which Medley has exclusive access, to further secure the loan. The outstanding principal balance and all accrued and unpaid interest on the Medley Term Loan are due and payable on February 19, 2019. As of March 31, 2015 the balance of the Medley Term Loan was $28.2 million. The Company recognized $195,000 of interest expense for the accretion of the discounts to the balance of the Medley Term Loan related to the commitment fees and the Medley Warrants and $155,000 of accrued interest for the three months ended March 31, 2015 and $84,000 of interest expense for the accretion of the discounts to the balance of the Medley Term Loan related to the commitment fees and the Medley Warrants and $70,000 of accrued interest for the period from February 19, 2014 (date of issuance) to March 31, 2014.

On January 30, 2015, the Company entered into an amendment to the Medley Term Loan, which provided additional notification and consent requirements, amends the minimum EBITDA covenant levels with respect to each of the six-month period ending March 31, 2015, the nine-month period ending June 30, 2015, the twelve-month period ending September 30, 2015 and the twelve-month period ending December 31, 2015, amends the definition of Fixed Charge Coverage Ratio and includes updates to certain disclosure schedules to the Medley Term Loan agreement.

Note 8. Fair Value Measurements

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2015, according to the valuation techniques the Company used to determine their fair values:

	Fair Value Measurement as of March 31, 2015
	Quoted Price in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
	Level 1		Level 2		Level 3
Assets (Recurring):
Pegasus Commitment	$	-	$	-	$	339,200
Liabilities (Recurring):
Riverwood Warrants	$	-	$	-	$	5,836,645
September 2012 Warrants		-		-		339,200
Pegasus Warrant		-		-		3,226,000
THD Warrant		-		-		411,074
Medley Warrants		-		-		1,749,254
Pegasus Guaranty Warrants		-		-		1,859,028
	$	-	$	-	$	13,421,201

The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the three months ended March 31, 2015:

				Realized and unrealized			Purchases,		Transfers
				gains (losses)			sales,		in
	Balance			included			issuances and		or out of		Balance
	December 31, 2014			in net loss			settlements		Level 3		March 31, 2015
Pegasus Commitment	$	720,000		$	(380,800	)	$	-	$	-	$	339,200
Riverwood Warrants		(2,352,027	)		(3,484,618	)		-		-		(5,836,645	)
September 2012 Warrants		(720,000	)		380,800			-		-		(339,200	)
Pegasus Warrant		(1,300,000	)		(1,926,000	)		-		-		(3,226,000	)
THD Warrant		(43,928	)		(367,146	)		-		-		(411,074	)
Medley Warrants		(577,065	)		(1,172,189	)		-		-		(1,749,254	)
Pegasus Guaranty Warrants		(643,924	)		(1,215,104	)		-		-		(1,859,028	)
Total	$	(4,916,944	)	$	(8,165,057	)	$	-	$	-	$	(13,082,001	)

10

The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the three months ended March 31, 2014:

				Realized and unrealized			Purchases, sales,			Transfers in
	Balance			gains (losses) included			issuances and			or out of		Balance
	December 31, 2013			in net loss			settlements			Level 3		March 31, 2014
Pegasus Commitment	$	1,407,335		$	432,665		$	-		$	-	$	1,840,000
Riverwood Warrants		(5,002,664	)		(2,053,415	)		-			-		(7,056,079	)
September 2012 Warrants		(1,407,335	)		(432,665	)		-			-		(1,840,000	)
Pegasus Warrant		(2,765,047	)		(1,134,953	)		-			-		(3,900,000	)
Series J Warrants		-			(26,134,232	)		(12,505,739	)		-		(38,639,971	)
Medley Warrants		-			(74,954	)		(3,170,361	)		-		(3,245,315	)
Pegasus Guaranty Warrants		-			(81,984	)		(3,336,574	)		-		(3,418,558	)
Total	$	(7,767,711	)	$	(29,479,538	)	$	(19,012,674	)	$	-	$	(56,259,923	)

Note 9. Stockholders’ Equity

For the three months ended March 31, 2015 and 2014, the Company recorded expense of $11,000 and $73,000, respectively, related to restricted stock awards to the Company’s directors.

On June 12, 2014, the Board approved the formation of a Scientific Advisory Board (the “SAB”) and issued restricted stock awards to each of the five members of the SAB as part of their compensation package. For the three months ended March 31, 2015, the Company recorded expense of $33,000 related to restricted stock awards to the Company’s SAB.

Warrants for the Purchase of Common Stock

As of March 31, 2015, the following warrants for the purchase of Common Stock were outstanding:

Warrant Holder	Reason for Issuance	Number of Common Shares		Exercise Price		Expiration Date
Investors in rights offering	Series D Warrants		1,072,617	$	2.95 to $2.96	March 3, 2022 through April 19, 2022
The Home Depot	Purchasing agreement		7,609,183	$	1.05	December 31, 2015 through 2018
RW LSG Management Holdings LLC	Riverwood Warrants		12,664,760	Variable		May 25, 2022
Certain other investors	Riverwood Warrants		5,427,751	Variable		May 25, 2022
Cleantech Europe II (A) LP	September 2012 Warrants		3,406,041	$	0.72	September 25, 2022
Cleantech Europe II (B) LP	September 2012 Warrants		593,959	$	0.72	September 25, 2022
Portman Limited	September 2012 Warrants		4,000,000	$	0.72	September 25, 2022
Aquillian Investments LLC	Private Placement Series H		830,508	$	1.18	September 25, 2017
Pegasus	Pegasus Warrant		10,000,000	Variable		May 25, 2022
Investors in Series J Follow-On Offering	Series J Warrants		185,500,000	$	0.001	January 3, 2019 through January 30, 2020
Medley	Medley Warrants		10,000,000	$	0.95	February 19, 2024
Pegasus	Pegasus Guaranty Warrants		10,000,000	$	0.50	February 19, 2024
			251,104,819

Note 10: Earnings (Loss) Per Share

In 2012, the Company determined that two classes of Common Stock had been established for financial reporting purposes only, with Common Stock attributable to controlling stockholders representing shares beneficially owned and controlled by Pegasus and the Common Stock attributable to noncontrolling stockholders representing the minority interest stockholders. For the three months ended March 31, 2015 and 2014, the Company computed net loss per share of noncontrolling stockholders and controlling stockholders of Common Stock using the two-class method. Net loss from operations is initially allocated based on the underlying common shares held by controlling and noncontrolling stockholders. The allocation of the net losses attributable to the Common Stock attributable to controlling stockholders is then reduced by the amount of the deemed dividend related to the warrants issued to the Pegasus Guarantors, while the allocation of net losses attributable to the Common Stock attributable to noncontrolling stockholders is increased by the amount of the deemed dividend related to the warrants issued to the Pegasus Guarantors.

11

The following table sets forth the computation of basic and diluted net loss per share of Common Stock:

	For the Three Months Ended March 31,
	2015						2014
	Controlling Stockholders			Noncontrolling Stockholders			Controlling Stockholders			Noncontrolling Stockholders
Basic and diluted net income per share:
Net loss attributable to common stock	$	(10,154,538	)	$	(3,446,552	)	$	(32,984,078	)	$	(7,109,885	)
Deemed dividends related to the Series J Preferred Stockattributable to all shareholders		(11,421,641	)		(3,876,619	)		(24,843,481	)		(5,355,138	)
Deemed dividends due to the issuance of Pegasus Guaranty Warrantsas compensation for guaranty provided by controlling shareholders		-			-			570,574			(570,574	)
Undistributed net loss	$	(21,576,179	)	$	(7,323,171	)	$	(57,256,985	)	$	(13,035,597	)
Basic and diluted weighted average number of common shares outstanding		287,758,558			97,668,138			170,973,536			36,854,212
Basic and diluted net loss per common share	$	(0.07	)	$	(0.07	)	$	(0.33	)	$	(0.35	)

Basic earnings per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding for the applicable period. The Series J Warrants have an exercise price of $0.001 per share of Common Stock, and are included in the weighted average number of shares of Common Stock outstanding as there are no conditions that must be satisfied before such warrant may be exercised into the shares of Common Stock underlying such warrants. Diluted earnings per share is computed in the same manner as basic earnings per share except the number of shares is increased to assume exercise of potentially dilutive stock options, unvested restricted stock and contingently issuable shares using the treasury stock method and convertible preferred shares using the if-converted method, unless the effect of such increases would be anti-dilutive. The Company had 204.0 million and 109.4 million common stock equivalents for the three months ended March 31, 2015 and 2014, respectively, which were not included in the diluted net loss per common share as the common stock equivalents were anti-dilutive, as a result of being in a net loss position.

Note 11: Related Party Transactions

Pegasus Capital is an affiliate of Pegasus IV and LSGC Holdings, which are the Company’s largest stockholders and beneficially owned approximately 88.7% of the Common Stock as of March 31, 2015.

On January 30, 2015, the Company issued an additional 11,525 units of Series J Securities, at a purchase price of $1,000 per Series J Security for aggregate proceeds of $11.5 million. The Series J Securities were issued pursuant to a subscription agreement between the Company and Holdings III, an affiliate of Pegasus Capital.

Note 12. Restructuring Expense

The following table summarizes the Company’s restructuring expense and related charges for the following periods ended March 31:

	For the Three Months Ended March 31,
	2015		2014
Broad based reduction of facilities and personnel (1)	$	83,704	$	114,276
Organization Optimization Initiative (2)		-		90,776
Total	$	83,704	$	205,052

(1)

These charges relate to a significant cost reduction plan initiated during the fourth quarter of 2013 that includes moving the majority of the Company’s manufacturing to its contract manufacturers in Asia, related workforce reductions in Satellite Beach, Florida and cost reductions in our foreign subsidiaries. The Company estimates it will incur $200,000 in additional expenses throughout this cost reduction plan, primarily related to additional headcount reductions. These additional costs are expected to be incurred in the first half of 2015.

(2)

In September 2011, the Company began implementing a restructuring plan designed to further increase efficiencies across the organization and lower the overall cost structure. This restructuring plan included a reduction in full time headcount in the United States, which was completed in October 2011. In 2012, the Company extended the restructuring plan to further increase efficiencies across the organization and lower its overall cost structure. The plan included a significant reduction in full time headcount in Mexico resulting from the Company’s continued shift of its manufacturing and production processes to the Company’s contract manufacturer in Mexico, the replacement of 10 members of management in the United States following the completion of the Series H and I Preferred Offering in May 2012 and the closing of the Company’s offices in the United Kingdom and Australia. For the three months ended March 31, 2014, these expenses relate to the final liquidation of the Australian entity.

12

As of March 31, 2015, the accrued liability associated with the restructuring and other related charges consisted of the following:

	Workforce			Excess			Other
	Reduction			Facilities			Exit Costs			Total
Accrued liability as of December 31, 2014	$	959,240		$	311,269		$	180,840		$	1,451,349
Charges		83,704			-			-			83,704
Payments		(422,377	)		(67,127	)		(6,053	)		(495,557	)
Accrued liability as of March 31, 2015	$	620,567		$	244,142		$	174,787		$	1,039,496

The remaining accrual of $1.0 million as of March 31, 2015 is expected to be paid during the year ending December 31, 2015.

The restructuring and other related charges are included in the line item restructuring expense in the condensed consolidated statement of operations and comprehensive loss.

Note 13. Concentrations of Credit Risk

For the three months ended March 31, 2015 and 2014, the Company had one customer whose revenue represented 80% and 78% of total revenue, respectively.

As of March 31, 2015 and December 31, 2014, the Company had one customer whose accounts receivable balance represented 81% and 66% of accounts receivable, net of allowances, respectively.

Note 14. Commitments and Contingencies

Legal Proceedings

The Company is subject to the possibility of loss contingencies arising in its business. Such contingencies are accounted for in accordance with ASC Topic 450, “Contingencies.” In determining loss contingencies, the Company considers the possibility of a loss and the ability to reasonably estimate the amount of such loss or liability. An estimated loss is recorded when it is considered probable that a liability has been incurred and when the amount of loss can be reasonably estimated. In the ordinary course of business, the Company is routinely a defendant in or party to various pending and threatened legal claims and proceedings. The Company believes that any liability resulting from these various claims, except as noted below, will not have a material adverse effect on its results of operations or financial condition; however, it is possible that extraordinary or unexpected legal fees could adversely impact the Company’s financial results during a particular period. During its ordinary course of business, the Company enters into obligations to defend, indemnify and/or hold harmless various customers, officers, directors, employees, and other third parties. These contractual obligations could give rise to additional litigation costs and involvement in court proceedings.

On June 22, 2012, Geveran Investments Limited (“Geveran”), one of the Company’s stockholders, filed a lawsuit against the Company and several others in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida. On October 30, 2012, the court entered an order transferring the lawsuit to the Ninth Judicial Circuit in and for Orange County, Florida. The action, styled Geveran Investments Limited v. Lighting Science Group Corp., et al., Case No. 12-17738 (07) (the “Geveran Case”), names the Company as a defendant, as well as Pegasus Capital and nine other entities affiliated with Pegasus Capital; Richard Weinberg, our former Director and former interim Chief Executive Officer and a former partner of Pegasus Capital; Gregory Kaiser, a former Chief Financial Officer; J.P. Morgan Securities, LLC (“J.P. Morgan”); and two employees of J.P. Morgan. Geveran seeks rescission of its $25.0 million investment in the Company, as well as recovery of interest, attorneys’ fees and court costs, jointly and severally against the Company, Pegasus Capital, Mr. Weinberg, Mr. Kaiser, J.P. Morgan and the two J.P. Morgan employees, for alleged violations of Florida securities laws. Geveran alternatively seeks unspecified money damages, as well as recovery of court costs, for alleged common law negligent misrepresentation against these same defendants. In August 2014, the court granted Geveran’s motion to amend their first amended complaint to assert a claim for punitive damages against the defendants.

13

On August 28, 2014, the court issued an Order Granting Plaintiff’s Motion for Partial Summary Judgment under its First Cause of Action for Violation of the Florida Securities and Investor Protection Act (the “August 28 Order”). As of May 14, 2015, the August 28 Order had not been entered. Once the August 28 Order is entered, the Company intends to appeal it. Together with the other defendants, the Company will have 30 days to post a bond during which time enforcement of the judgment would be stayed. The Company plans to have a bond posted to secure the judgment, which should result in the automatic stay of enforcement through the appeal process.

While the court granted partial summary judgment in favor Geveran and the outcome of any litigation is inherently difficult to predict, the Company currently believes that it has strong defenses against Geveran’s claims. The Company has retained counsel, denies liability in connection with this matter and intends to continue to vigorously defend itself against the claims asserted by Geveran. Nonetheless, the amount of possible loss, if any, cannot be reasonably estimated at this time. The outcome, if unfavorable, could have a material adverse effect on the Company’s financial position. The Company believes that, subject to the terms and conditions of the relevant policies (including retention and policy limits), directors and officers’ insurance coverage will be available to cover the substantial majority of its legal fees and costs in this matter. However, given the unspecified nature of Geveran’s maximum damage claims, insurance coverage may not be available for, or such coverage may not be sufficient to fully pay, a judgment or settlement in favor of Geveran.Based upon the terms of an indemnification agreement described below, the Company has also paid, and is likely to pay in the in the future, reasonable legal expenses incurred by J.P. Morgan and its affiliates in this lawsuit in connection with the engagement of J.P. Morgan as placement agent for the private placement with Geveran. Such payments are not covered by the Company’s insurance coverage. The engagement letter executed with J.P. Morgan provides that the Company will indemnify J.P. Morgan and its affiliates from liabilities relating to J.P. Morgan’s activities as placement agent, unless such activities are finally judicially determined to have resulted from J.P. Morgan’s bad faith, gross negligence or willful misconduct.

The Company is also a defendant in action brought by GE Lighting Solutions LLC in Federal District Court for the Northern District of Ohio in or about January 2013. GE Lighting asserts a claim of patent infringement against the Company under U.S Patent No. 6,787,999, entitledLED-Based ModularLamp, and U.S. Patent No. 6,799,864, entitledHigh Power LED Power Pack for Spot Module Illumination, and seeks monetary damages and an injunction. The Company believes that it has strong defenses against plaintiff’s claims.  The Company has retained counsel, denies liability in connection with this matter and intends to continue to vigorously defend itself against the claims asserted by GE Lighting. However, there is no assurance that the Company will be successful in defending against this action. The outcome, if unfavorable, could have a material adverse effect on the Company’s financial position. Even if the outcome is favorable, this litigation could result in substantial costs to the Company, could be a distraction to management and could harm the Company’s financial position.

In addition, the Company may be a party to a variety of legal actions, such as employment and employment discrimination-related suits, employee benefit claims, breach of contract actions, tort claims, shareholder suits, including securities fraud, intellectual property related litigation, and a variety of legal actions relating to its business operations. In some cases, substantial punitive damages may be sought. The Company currently has insurance coverage for certain of these potential liabilities. Other potential liabilities may not be covered by insurance, insurers may dispute coverage or the amount of insurance may not be sufficient to cover the damages awarded. In addition, certain types of damages, such as punitive damages, may not be covered by insurance and insurance coverage for all or certain forms of liability may become unavailable or prohibitively expensive in the future.

14

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This section and other parts of thisQuarterly Report onForm 10-Q(this “Form 10-Q”)contain forward-looking statements that involve risks and uncertainties. Forward-looking statements can be identified by words such as “expects,” “anticipates,” “could,” “intends,” “seeks,” “estimates,” “believes,” “plans,” “predicts,” and similar terms. Forward-looking statements are not guarantees of future performance and our actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the U.S. Securities and Exchange Commission (the“SEC”) onMarch 31, 2015 (the “Form 10-K”) and the Condensed Consolidated Financial Statements and notes thereto included elsewhere in this Form 10-Q. Our results of operations in any past period should not be considered indicative of the results to be expected for future periods. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Form 10-Q. The forward-looking statements in this document are intended to be subject to the safe harbor protection provided by Sections 27A of the Securities Act of 1933, as amended (the “Securities Act”) and 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.

Company Overview

We are an innovator and provider of light emitting diode (“LED”) lighting technology. We design, develop, manufacture and market advanced illumination products that use LEDs as their exclusive light source. Our product portfolio includes LED-based retrofit lamps (replacement bulbs) used in existing light fixtures as well as purpose-built LED-based luminaires (light fixtures). Our lamps and luminaires are used for many common indoor and outdoor residential, commercial, industrial and public infrastructure lighting applications. We have also developed LED lighting technology whose light and color are tuned to achieve specific biological effects. We believe our proprietary technology, unique designs and key relationships throughout the LED lighting supply chain position us favorably to capitalize on the expanding acceptance of LEDs as a lighting source.

Our strategic plan for the next three fiscal years consists of creating strong digital lighting brands in the consumer, residential, commercial and industrial markets. We believe that developing innovative and differentiated brands will deliver strong financial returns and a more loyal user base that is less price sensitive. We intend to continue to implement a nimble and agile “go-to-market” business model and manufacturing and product development system to streamline the processes used to introduce new products. We also intend to continue focusing on developing breakthrough innovation and on becoming a market maker in targeted value-added, high-margin segments within the lighting market. Finally, we plan to reduce our cost structure, preserve cash flow and strengthen liquidity to enhance our financial position.

Over the past few years, we have focused on expanding and optimizing our global supply chain to meet forecasted demand for our products while addressing the inefficiencies that have compressed our gross margin and overall financial performance in prior periods such as costs incurred to expedite the production or delivery of component parts. We anticipate long-term gross margin improvement as we continue to execute on our initiatives. We completed one of our most critical initiatives in 2014 with the transition of the manufacturing of our high volume lamps from Mexico and Satellite Beach, Florida to our contract manufacturing partners in Asia, from which we source the majority of our components. We began this transition in the third quarter of 2013, and completed it during the first half of 2014. We anticipate these actions will result in improved gross margin, as well as a more optimized product supply in future periods.

We continue to focus on increasing our brand awareness and improving our product promotion through prominent displays at our retailers and by conducting high visibility national media promotions with our key customers. In October 2013, we launched our GoodNight and Awake&Alert lights, the world’s first biologically corrected consumer lighting products. The GoodNight light has a patented spectral filter that greatly reduces blue light and supports the body’s natural melatonin production designed to naturally promote healthy sleep patterns. The Awake&Alert light has a blue enriched spectrum designed to naturally enhance alertness. We continue to work with major media outlets, grant interviews and work with key consumer influencers to gain greater visibility for our brand and our scientifically proven technology. In 2013 we were featured in Men’s Health magazine,Condé Nast Traveler, National Geographic, Popular Science, Wall Street Journal online and ABC newswire. During 2014 we were featured on the Dr. OZ Show, The Rachael Ray Show, Live! With Kelly and Michael, Architectural SSL and other prominent national and local news affiliates.  Additionally, in 2014, we were ranked in the Top 500 of Deloitte’s 2014 Technology Fast 500™ in North America for the third consecutive year.

15

Financial Results

The following table sets forth our revenue, cost of goods sold and gross profit for the three months ended March 31, 2015 and 2014:

	Three Months Ended March 31,
	2015			2014
Revenue	$	19,371,545		$	25,925,841
Cost of goods sold		16,441,297			23,462,953
Gross profit	$	2,930,248		$	2,462,888
GAAP gross profit percentage		15.1	%		9.5	%

Our revenue is primarily derived from sales of our LED-based retrofit lamps and luminaires. Our revenue decreased $6.6 million during the three months ended March 31, 2015, as compared to the three months ended March 31, 2014. This decrease in revenue primarily resulted from a $4.5 million decrease in sales to The Home Depot, Inc. (“The Home Depot”) and a $2.0 million decrease in sales to other customers for the three months ended March 31, 2015. Such decreases were partially attributable to delayed deliveries that were hampered by port disruptions on the west coast and harsh winter weather, which impacted the transportation of goods. Further, our revenue was negatively impacted during the three months ended March 31, 2015 due to the limited availability of a product that was upgraded during the period. In addition, revenue for the three months ended March 31, 2015 decreased as compared to the three months ended March 31, 2014 as a result of the decrease in sales of certain products that were introduced in early 2014. During the three months ended March 31, 2015, our gross margin improvement was primarily attributed to our transition to lower cost contract manufacturers in Asia, which was substantially complete as of June 30, 2014.

We continue to pursue new relationships with retailers and original equipment manufacturers (“OEMs”) to help increase our sales. In addition, we have significantly increased the roster of distributors and independent sales agents that sell our products and added experienced professionals to our direct sales force to increase the frequency and impact of our activities with key national accounts that are targets for potential adoption of LED lighting.

Our gross margins are principally driven by the mix and quantity of products we sell to The Home Depot and our other customers. Our financial results are dependent upon the operating costs associated with our supply chain, including materials, labor and freight, and the level of sales, distribution and administrative, research and development and other operating expense. We continuously seek to improve our products and to bring new products to market. As a result, many of our products have short life cycles and therefore, product life cycle planning is critical. These circumstances can lead to inventory write-downs and provisions for expected losses on non-cancellable purchase commitments. When these circumstances are present, we may also incur additional expense as we adjust our supply chain and product life-cycle planning.

Non-GAAP Financial Measures

Although our condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), we believe the following non-GAAP financial measures provide additional information that is useful to the assessment of our operating performance and trends. As part of our ongoing review of financial information related to our business, we regularly use non-GAAP measures, particularly non-GAAP adjusted gross margin and non-GAAP adjusted operating expense as a percentage of revenue, as we believe they provide meaningful insight into our business and useful information with respect to the results of our operations. These non-GAAP financial measures are not in accordance with, nor are they a substitute for, the comparable GAAP financial measures, and are intended to supplement our financial results that are prepared in accordance with GAAP.

16

The adjusted presentation below is used by management to measure our business performance and provides useful information regarding the trend in gross margin percentage based on revenue from sales of our products to customers. Excluding non-cash expense for stock based compensation, restructuring expense and depreciation and amortization, total operating expense decreased by 43.7% for the three months ended March 31, 2015, while revenue decreased 25.3% compared to the three months ended March 31, 2014. Total non-GAAP adjusted operating expense represented 27.7% of revenue for the three ended March 31, 2015 as compared to 36.7% of revenue for the three ended March 31, 2014. For the three months ended March 31, 2015, the decrease in non-GAAP adjusted operating expense as a percentage of revenue was due to the decrease in operating expense, primarily driven by reductions in personnel-related expense, transportation and other selling costs.

	Three Months Ended March 31,
	2015			2014
Revenue	$	19,371,545		$	25,925,841
Cost of goods sold		16,441,297			23,462,953
Deduct:
Provisions for inventory write-offs		271,452			689,637
Adjusted cost of goods sold		16,169,845			22,773,316
Adjusted gross profit	$	3,201,700		$	3,152,525
Non-GAAP adjusted gross margin percentage		16.5	%		12.2	%
Total operating expense		6,866,670			11,791,424
Less:
Issuance of restricted stock and stock options for directorscompensation		11,101			73,348
Non-cash stock option and restricted stockcompensation expense		905,396			916,657
Restructuring expense		83,704			205,052
Depreciation and amortization		506,072			1,076,010
Total operating expense, excluding stock based compensation,restructuring and depreciation and amortization	$	5,360,397		$	9,520,357
GAAP operating expense as apercentage of revenue		35.4	%		45.5	%
Non-GAAP adjusted operating expense as apercentage of revenue		27.7	%		36.7	%

During 2013 and the first half of 2014, we adapted our supply chain and logistics processes to improve our ability to provide more efficient service to our customers and focus our efforts on developing innovative products. We continued to make improvements in our forecasting and finished goods inventory management, continued the transition of our manufacturing processes to lower cost contract manufacturers in Asia and continued to enhance our new product innovation process.

We believe that the enhancements to our business initiated in 2013 and continued throughout 2014 improved our management and manufacturing infrastructure, expanded our ability to source components and manufacture our products internationally and positioned us for organic growth. We believe these improvements will position us to capitalize on the innovative, science based and creative engineering talent at our Melbourne, Florida headquarters, which we believe provides us with a competitive advantage. In addition to developing products targeted at mainstream retail and commercial lighting, we will look to expand our product offerings to compete across multiple industry verticals.

17

LED Lighting Industry Trends

There are a number of industry factors that affect our business and results of operations including, among others:

● Rate and extent of adoption of LED lighting products. Our potential for growth will be driven by the rate and extent of adoption of LED lighting within the general illumination market and our ability to affect this rate of adoption. Although LED lighting is relatively new and faces significant challenges before achieving widespread adoption, it has grown in recent years. Innovations and advancements in LED lighting technology that improve product performance and reduce product cost continue to enhance the value proposition of LED lighting for general illumination and expand its potential commercial applications.

● External legislation and subsidy programs concerning energy efficiency. The United States and many countries in the European Union and elsewhere, among others, have already instituted, or have announced plans to institute, government regulations and programs designed to encourage or mandate increased energy efficiency in lighting. These actions include in certain cases banning the sale after specified dates of certain forms of incandescent lighting, which is advancing the adoption of more energy efficient lighting solutions such as LEDs. In addition, the growing demand for electricity is increasingly driving utilities and governmental agencies to provide financial incentives such as rebates for energy efficient lighting technologies in an effort to mitigate the need for investments in new electrical generation capacity.While this trend is generally positive for us, from time to time there have been political efforts in the United States to change or limit the effectiveness of these regulations.

● Intellectual property. LED market participants rely on patented and non-patented proprietary information relating to product development, manufacturing capabilities and other core competencies of their business. Protection and licensing of intellectual property is critical. Therefore, LED lighting industry participants often take steps such as additional patent applications, confidentiality and non-disclosure agreements as well as other security measures. To enforce or protect intellectual property rights, market participants commonly commence or threaten litigation.

● Intense and constantly evolving competitive environment.Competition in the LED lighting market is intense. Many companies have made significant investments in LED lighting development and production equipment. Traditional lighting companies and new entrants are investing in LED based lighting products as LED adoption has gained momentum. Product pricing pressures is significant and market participants often undertake pricing strategies to gain or protect market share, enhance sales of their previously manufactured products and open new applications to LED based lighting solutions. To remain competitive, market participants must continuously increase product performance and reduce costs.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and consolidated results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expense and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based upon historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates.

A critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations. Specifically, critical accounting estimates have the following attributes: (i) they require us to make assumptions about matters that are highly uncertain at the time of the estimate; and (ii) different estimates we could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.

18

Estimates and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes. These changes have historically been minor and have been included in the financial statements as soon as they became known.

We believe that our critical accounting policies relate to our more significant estimates and judgments used in the preparation of our condensed consolidated financial statements. Our Annual Report on Form 10-K for the year ended December 31, 2014 contains a discussion of these critical accounting policies. There have been no significant changes in our critical accounting policies since December 31, 2014. See also Note 1 to our unaudited condensed consolidated financial statements for the three months ended March 31, 2015 as set forth herein.

Results of Operations

Three Months EndedMarch 31, 2015Compared to the Three Months EndedMarch 31, 2014

The following table sets forth statement of operations data expressed as a percentage of total revenue for the periods indicated:

	Three Months Ended March 31,						Variance						Percentage of Revenue
	2015			2014			$			%			2015			2014
Revenue	$	19,371,545		$	25,925,841			(6,554,296	)		-25.3	%		100.0	%		100.0	%
Cost of goods sold		16,441,297			23,462,953			(7,021,656	)		-29.9	%		84.9	%		90.5	%
Selling, distribution and administrative		5,095,581			8,966,338			(3,870,757	)		-43.2	%		26.3	%		34.6	%
Research and development		1,181,313			1,544,024			(362,711	)		-23.5	%		6.1	%		6.0	%
Restructuring expense		83,704			205,052			(121,348	)		-59.2	%		0.4	%		0.8	%
Depreciation and amortization		506,072			1,076,010			(569,938	)		-53.0	%		2.6	%		4.2	%
Interest income		-			411			(411	)		-100.0	%		0.0	%		0.0	%
Interest expense, including related party		(1,600,660	)		(1,343,225	)		(257,435	)		19.2	%		-8.3	%		-5.2	%
Increase in fair value of liabilities under derivative contracts		(8,100,772	)		(29,479,538	)		21,378,766			-72.5	%		-41.8	%		-113.7	%
Other income, net		36,764			56,925			(20,161	)		-35.4	%		0.2	%		0.2	%
Net loss	$	(13,601,090	)	$	(40,093,963	)		26,492,873			-66.1	%		-70.2	%		-154.6	%

Revenue

Revenue decreased $6.6 million, or 25.3%, to $19.4 million for the three months ended March 31, 2015 from $25.9 million for the three months ended March 31, 2014. The decrease in revenue was primarily a result of a $4.5 million decrease in sales to The Home Depot and a $2.0 million decrease in sales to multiple other customers for the three months ended March 31, 2015 as compared to sales for the three months ended March 31, 2014. The decrease in revenue was partially attributable to delayed deliveries that were hampered by port disruptions on the west coast and harsh winter weather, which impacted the transportation of goods. Further, our revenue was negatively impacted during the three months ended March 31, 2015 due to the limited availability of a product that was upgraded during the period. In addition, revenue for the three months ended March 31, 2015 decreased as compared to the three months ended March 31, 2014 as a result of the decrease in sales of certain products that were introduced in early 2014.

Cost of Goods Sold

Cost of goods sold decreased $7.0 million, or 29.9%, to $16.4 million for the three months ended March 31, 2015 from $23.5 million for the three months ended March 31, 2014. The decrease in cost of goods sold was primarily due to the reduction in revenue as well as the impact of our transition to lower cost contract manufacturers in Asia during the three months ended March 31, 2015 compared to the three months ended March 31, 2014. Cost of goods sold as a percentage of revenue decreased for the three months ended March 31, 2015 to 84.9% (or a gross margin percentage of 15.1%) as compared to 90.5% (or a gross margin percentage of 9.5%) for the three months ended March 31, 2014.

Selling, Distribution andAdministrative

Selling, distribution and administrative expense decreased $4.1 million, or 44.6%, to $5.1 million for the three months ended March 31, 2015 from $9.0 million for the three months ended March 31, 2014, and decreased as a percentage of revenue to 26.3% for the three months ended March 31, 2015 from 35.5% for the three months ended March 31, 2014. The decrease in selling, distribution and administrative expense was due to a $1.2 million decrease in fees paid to outside consultants and agents, a $1.1 million decrease in personnel-related expense due to the workforce reductions in 2014, a $489,000 decrease in professional fees, a $377,000 decrease in facilities related expenses due to our move to a new location, a $351,000 decrease in freight and logistics, a $233,000 decrease in personnel costs due to the winding down of our operations in Mexico, India and the Netherlands and a decrease of $264,000 due to miscellaneous cost cutting measures.

19

Research and Development

Research and development expense decreased $363,000, or 23.5%, to $1.2 million for the three months ended March 31, 2015 from $1.5 million for the three months ended March 31, 2014, and increased as a percentage of revenue to 6.1% for the three months ended March 31, 2015 from 6.0% for the three months ended March 31, 2014. The decrease in research and development expense was primarily due to a $255,000 decrease in personnel related expense driven by the workforce reductions in 2014 and a $68,000 decrease in external testing expense as we continued our efforts to reduce our costs in 2015.

Restructuring

Restructuring expense was $84,000 for the three months ended March 31, 2015 compared to $205,000 for the three months ended March 31, 2014. Restructuring expense for the three months ended March 31, 2015 consisted of severance and termination benefits. Restructuring expense for the three months ended March 31, 2014 consisted of $182,000 in severance and termination benefits related to headcount reductions in the United States and a net charge of $114,000 related to the final liquidation of our Australian entity, partially offset by a reduction in estimated costs related to the winding down of our Indian subsidiary.

Depreciation and Amortization

Depreciation and amortization expense decreased $570,000, or 53.0%, to $506,000 for the three months ended March 31, 2015 from $1.1 million for the three months ended March 31, 2014. The decrease in depreciation and amortization expense was primarily a result of the impairment of manufacturing equipment and tools and molds during the year ended December 31, 2014 related to our restructuring efforts, which included a broad based reduction of facilities and personnel.

Interest Expense, Including Related Party

Interest expense, including related party interest, increased $257,000, or 19.2%, to $1.6 million for the three months ended March 31, 2015 from $1.3 million for the three months ended March 31, 2014. The increase in interest expense was primarily due to the impact of the Company’s five-year term loan (as amended from time to time, the “Medley Term Loan”)with Medley Capital Corporation (“Medley”). Interest expense for the three months ended March 31, 2015 consisted of $1.2 million of interest expense and fees related to the Medley Term Loan, $138,000 of non-cash interest expense related to the amortization of the Pegasus Guaranty (as defined below) and $226,000 of interest expense and fees related to thethree year asset based revolving credit facility (as amended from time to time, the “FCC ABL”) entered into on April 25, 2014 with FCC, LLC d/b/a First Capital (“First Capital”). . Interest expense for the three months ended March 31, 2014 consisted of $590,000 of interest expense and fees related to the Medley Term Loan, $61,000 of non-cash interest expense related to the amortization of the Pegasus Guaranty $264,000 of interest expense and fees related to the Company’s asset-based revolving credit facility (as amended, the “Wells Fargo ABL”) with Wells Fargo Bank N.A. (“Wells Fargo”)and $426,000 of interest expense related to the Second Lien Letter of Credit Facility (the “Ares Letter of Credit Facility”), dated as of September 20, 2011, pledged in favor of Wells Fargo by or for the account of Ares Capital Corporation.

Increasein Fair Value of Liabilities under Derivative Contracts

On February 19, 2014, in connection with the consummation of the transactions contemplated by the Medley Loan Agreement, we issued a warrant to purchase 5,000,000 shares of our common stock, par value $0.001 per share (the “Common Stock”) to each of Medley and Medley Opportunity Fund II LP (the “Medley Warrants”). The Medley Warrants were accounted for as liabilities and their fair value was determined using the Black Scholes valuation method. Pegasus Capital Partners IV, L.P. and Pegasus Capital Partners V, L.P. (collectively, the “Pegasus Guarantors”) have agreed to provide a guaranty of our obligations under the Medley Loan Agreement in favor of Medley (the “Pegasus Guaranty”). As consideration for the Pegasus Guaranty, on February 19, 2014, we issued a warrant to purchase 5,000,000 shares of Common Stock to each of the Pegasus Guarantors (the “Pegasus Guaranty Warrants”). The Pegasus Guaranty Warrants were accounted for as liabilities and their fair value was determined using the Black Scholes valuation method. The fair value of the outstanding Medley Warrants and the Pegasus Guaranty Warrants increased by $2.4 million for the three months ended March 31, 2015 and increased by $157,000 for the period from February 19, 2014 (the date of issuance of the Medley and Pegasus Guaranty Warrants) to March 31, 2014. This change in fair value is impacted by a number of factors, including changes in the trading price of our Common Stock and changes in risk-free interest rates.

20

On September 11, 2013, we issued shares of our Series J Convertible Preferred Stock (“Series J Preferred Stock”) to LSGC Holdings II LLC (“Holdings II”) and certain other purchasers and issued a warrant to Holdings II (the “Pegasus Warrant”). The Pegasus Warrant was accounted for as a liability and its fair value was determined using the Monte Carlo valuation method. On May 25, 2012, we issued shares of our Series H Convertible Preferred Stock (the “Series H Preferred Stock”) to RW LSG Holdings LLC, an affiliate of Riverwood LSG Management Holdings LLC and Riverwood Capital Partners L.P. (collectively with their affiliates, “Riverwood”), and certain other purchasers and issued warrants to Riverwood (the “Riverwood Warrant”). The Riverwood Warrant was accounted for as a liability and its fair value was determined using the Monte Carlo valuation method. The fair value of the outstanding Pegasus Warrant and the Riverwood Warrant increased by $5.4 million for the three months ended March 31, 2015 and increased by $3.2 million for the three months ended March 31, 2014. These changes in fair value are impacted by a number of factors, including the change of the strike price of the Riverwood Warrant and the Pegasus Warrant due to the issuance of the Series J Preferred Stock and Series J Warrants, changes in the trading price of our Common Stock and changes in risk-free interest rates.

Between January 3, 2014 and March 7, 2014, we issued an aggregate of 17,475 units of our securities (the “Series J Securities”) with each Series J Security consisting of (i) one share of our Series J Preferred Stock and (ii) a warrant to purchase 2,650 shares of our Common Stock at an exercise price of $0.001 per share (the “Series J Warrants”). The Series J Warrants were accounted for as liabilities and their fair value as of March 31, 2014, was determined using the Black Scholes valuation method. The fair value of the outstanding Series J Warrants increased by $26.1 million for the period from the date of issuance of the Series J Warrants to March 31, 2014. This change in fair value is impacted primarily by the valuation of the Series J Warrants as of March 31, 2014 based on the Black Scholes valuation method as compared to fair value at date of issuance based on an allocation of the cash received for the Series J Securities between the Series J Preferred Stock and the Series J Warrants.

Other Income, Net

Other income, net decreased $20,000 for the three months ended March 31, 2015 to $37,000 compared to $57,000 for the three months ended March 31, 2014. Other income for the three months ended March 31, 2015 consisted primarily of $150,000 in miscellaneous income, partially offset by a $91,000 foreign exchange loss and $25,000 of miscellaneous expense. Other income for the three months ended March 31, 2014 consisted of a $44,000 foreign exchange gain and $12,000 of miscellaneous income.

Liquidity and Capital Resources

We continue to experience significant net losses as well as negative cash flows from operations, resulting in an accumulated deficit of $813.9 million and stockholders’ deficit of $511.4 million as of March 31, 2015. Our cash expenditures primarily relate to procurement of inventory and payment of salaries, benefits and other operating costs. Our primary sources of liquidity have historically been borrowings from various lenders and sales of Common Stock and preferred stock to, and short-term loans from, affiliates of Pegasus Capital Advisors, L.P. (“Pegasus Capital”), including Pegasus Partners IV, L.P. (“Pegasus IV”), LSGC Holdings LLC (“LSGC Holdings”), Holdings II, LSGC Holdings III LLC (“Holdings III”) and PCA LSG Holdings, LLC (“PCA Holdings” and collectively with Pegasus Capital, Pegasus IV, LSGC Holdings, Holdings II, Holdings III and their affiliates, “Pegasus”). Pegasus is the Company’s controlling stockholder. While Pegasus has led many of our capital raises, the offerings of our Series H Preferred Stock, Series I Convertible Preferred Stock (the “Series I Preferred Stock”) and Series J Preferred Stock also involved and/or were led by parties other than Pegasus.

As of March 31, 2015, we had cash and cash equivalents of $549,000 and an additional $3.0 million in restricted cash subject to a cash collateral dominion agreement pursuant to the Medley Term Loan. The FCC ABL provides us with a maximum borrowing capacity of $22.5 million, which capacity is based on a formula of eligible accounts receivable and inventory. We are required to comply with certain specified EBITDA requirements, maintain a specified lamp sourcing percentage and comply with maximum capital expenditure limits. As of March 31, 2015, we had $11.3 million outstanding under the FCC ABL and additional borrowing capacity of $4.5 million.

On January 30, 2015, we issued an additional 11,525 units of our Series J Securities, at a purchase price of $1,000 per Series J Security for aggregate proceeds of $11.5 million. These Series J Securities were issued pursuant to a subscription agreement with Holdings III.

21

Commencing on September 25, 2015, Riverwood and Pegasus will have the right to cause us to redeem their shares of Series H Preferred Stock and Series I Preferred Stock, respectively. If either Riverwood or Pegasus elects to cause us to redeem its shares of Series H Preferred Stock or Series I Preferred Stock, all other holders of the applicable series will have the right to redeem their shares of Series H Preferred Stock or Series I Preferred Stock, respectively. In addition, commencing 10 business days after September 25, 2015, each of Portman Limited and affiliates of Zouk Holdings Limited, jointly, has a contractual right to require us to redeem its shares of Series H Preferred Stock. We are also required to redeem the outstanding shares of our Series J Preferred Stock (a) subject to certain limited exceptions, immediately prior to the redemption of the Series H Preferred Stock, Series I Preferred Stock or any other security that ranks junior to, or pari passu with, the Series J Preferred Stock and (b) on November 14, 2019, at the election of the holders of Series J Preferred Stock(a “Special Redemption”). Each holder of our preferred stock would also have the right to require us to redeem such shares upon our uncured material breach of our obligations under our outstanding indebtedness or the uncured material breach of the terms of the certificates of designation governing our preferred stock. In total, our maximum payment obligation in the event of a redemption of all the Series H, I and J Preferred Stock is $492.0 million. Finally, we would be required to repay our outstanding obligations under the Medley Term Loan and the FCC ABL prior to any such redemption of shares of Series H, I or J Preferred Stock. As of March 31, 2015, the aggregate borrowings outstanding under these loan facilities was $39.5 million.

Any redemption of the Series H Preferred Stock, Series I Preferred Stock or Series J Preferred Stock would be limited to funds legally available therefor under Delaware law. The certificates of designation governing our preferred stock provide that if there is not a sufficient amount of cash or surplus available to pay for a redemption of Series H Preferred Stock, Series I Preferred Stock or Series J Preferred Stock, then the redemption shall be paid out of the remaining assets of the Company. In addition, the certificate of designation governing the Series J Preferred Stock provides that we are not permitted or required to redeem any shares of Series J Preferred Stock for so long as such redemption would result in an event of default under our credit facilities. If we do not have sufficient capital available to redeem the Series J Preferred Stock in connection with a Special Redemption of the Series J Preferred Stock, we will be required to issue a non-interest bearing note or notes (payable 180 days after issuance) in the principal amount of the liquidation amount of any shares of Series J Preferred Stock not redeemed by the Company in connection with such Special Redemption, subject to certain limitations imposed by Delaware law governing distributions to stockholders. As of March 31, 2015, based solely on a review of our balance sheet, we did not have legally available funds under Delaware law to satisfy a redemption of our Preferred Shares. In addition, based solely on our projected balance sheet as of September 25, 2015, we do not believe that we will have legally available funds on or before September 25, 2015 to satisfy any such redemption.

We continue to face challenges in our efforts to achieve positive cash flows from operations and profitability. Our ability to meet our obligations in the ordinary course of business is dependent upon establishing profitable operations, which may be supplemented by any additional funds raised through public or private financing or increased borrowing capacity. . Our current business plan includes a focus on increasing revenue by updating and expanding our product offerings and capitalizing on the known product needs of our existing customers, improving gross margins by significantly leveraging contract manufacturers in Asia and reducing operating costs, primarily through the restructuring initiated in 2013 and continued throughout 2014. In future periods, if we do not adequately execute upon our business plan or our assumptions or forecasts do not prove to be accurate, we could exhaust our available capital resources, which could require us to seek additional sources of liquidity or further reduce our expenditures to preserve our cash. Our sources of liquidity may not be available in an amount or on terms that are acceptable to us, if at all.

22

Cash Flows

The following table summarizes our cash flow activities for the three months ended March 31, 2015 and 2014:

	Three Months Ended March 31,
Cash flow activities:	2015			2014
Net cash used in operating activities	$	(17,192,978	)	$	(24,795,543	)
Net cash used in investing activities		(94,724	)		(5,495	)
Net cash provided by financing activities		16,224,437			18,833,842

Operating Activities

Cash used in operating activities is net loss adjusted for certain non-cash items and changes in certain assets and liabilities. Net cash used in operating activities decreased to $17.2 million for the three months ended March 31, 2015 from $24.8 million for the three months ended March 31, 2014. Net cash used in operating activities for the three months ended March 31, 2015 included certain non-cash reconciliation items comprised primarily ofan $8.1 million net increase in fair value of derivative contracts, $916,000 of stock-based compensation expense, $684,000 in amortization of debt issuance costs, accretion and interest accrual primarily on the FCC ABL and the Medley Term Loan, $506,000 in depreciation and amortization and $271,000 in inventory write-downs. For the three months ended March 31, 2014, net cash used in operating activities included certain non-cash reconciliation items comprised primarily of a $29.5 million increase in fair value of derivative contracts, $1.1 million in depreciation and amortization, $990,000 of stock-based compensation expense, a $690,000 inventory write-down and a $91,000 reduction in revenue for the fair value of the portion of the THD Warrant expected to vest during the period.

Changes in working capital also contributed to the decrease in net cash used in operating activities for the three months ended March 31, 2015 as compared to the three months ended March 31, 2014. In the aggregate, working capital changes totaled a net use of cash of $14.2 million in the three months ended March 31, 2015 compared to a net use of cash of $17.3 million in the three months ended March 31, 2014. For the three months ended March 31, 2015, the working capital changes consisted primarily of a decrease in accounts payable of $9.1 million, an increase in inventories of $5.5 million and a decrease in accrued expense and other liabilities of $920,000, which were partially offset by a $1.1 million decrease in prepaid expenses. For the three months ended March 31, 2014 the working capital changes consisted primarily of an increase in accounts receivable of $9.5 million, an increase in inventories of $3.45 million, an increase in accounts payable of $2.0 million and an increase in other current and long-term assets of $1.9 million, which were partially offset by a $1.1 million decrease in prepaid expenses.

Investing Activities

Cash used in investing activities primarily relates to the purchase of property and equipment and capitalized patents. Net cash used in investing activities was $95,000 and $5,000 for the three months ended March 31, 2015 and 2014, respectively. The cash used in investing activities for the three months ended March 31, 2015 was primarily due to capitalized patents of $92,000. The cash used in investing activities for the three months ended March 31, 2014 was primarily due to capitalized patents of $222,000, purchases of property and equipment of $153,000, partially offset by proceeds from sale of property and equipment of $370,000.

Financing Activities

Cash provided by financing activities has historically been composed of net proceeds from various debt facilities and the issuance of Common Stock and preferred stock. Net cash provided by financing activities was $16.2 million and $18.8 million for the three months ended March 31, 2015 and 2014, respectively. The cash provided by financing activities for the three months ended March 31, 2015included proceeds from the issuance of Series J Securities for aggregate proceeds of $11.5 million and net draws on our lines of credit and other short term borrowings of $5.0 million, partially offset by $135,000 in fees incurred in connection with the issuance of Series J Securities in January 2015. The cash provided by financing activities for the three months ended March 31, 2014 included proceeds of $29.8 million on the Medley Term Loan and the issuance of Series J Preferred Stock for $17.5 million, partially offset by net payments on our lines of credit and other short term borrowings, including the repayment of $30.2 million on the Wells Fargo ABL and the Ares Letter of Credit Facility and $218,000 in fees and commissions paid in connection with the issuance of Series J Securities.

23

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”)) that are designed to provide reasonable assurance that the information required to be disclosed by us in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (who is also our Principal Financial and Accounting Officer at this time (the “Certifying Officer”)), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

We carried out an evaluation under the supervision and with the participation of our management, including theCertifying Officer, of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our management, including the Certifying Officer, concluded that, as of March 31, 2015, our disclosure controls and procedures were not effective at a reasonable assurance level because the remediation plans to address the material weaknesses identified in our Annual Report on Form 10-K for the year ended December 31, 2014 have not been fully tested.

Changes in Internal Control over Financial Reporting

Subsequent to December 31, 2014, the following are among the key actions taken to our internal controls, which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting:

● We have reemphasized the importance of consistent application of the controls over the spreadsheet formulas used in the inventory valuation and enhanced the training of the personnel responsible for preparing and reviewing the spreadsheet; and

● We have implemented a reconciliation and confirmation process for our in-transit inventory on a monthly basis, as well as provided additional training of the personnel responsible for preparing and reviewing these transactions.

Although these actions have not been fully tested, we believe we have remediated the material weaknesses described in our Annual Report on Form 10-K for the year ended December 31, 2014.

Our leadership team, together with other senior executives and our board of directors, is committed to achieving and maintaining a strong control environment, high ethical standards and financial reporting integrity. This commitment has been and will continue to be communicated to, and reinforced with, our employees. Under the direction of our board of directors, management will continue to review and make changes to the overall design of our internal control environment, as well as policies and procedures to improve the overall effectiveness of our internal control over financial reporting and our disclosure controls and procedures.

Other than the measures discussed above, there were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Except as listed below, other items in Part II are omitted because the items are inapplicable or require no response.

Item 6. Exhibits

 See “Exhibit Index” for a description of our exhibits.

24

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	LIGHTING SCIENCE GROUP CORPORATION
Date: May 15, 2015	By	/s/Edward D. Bednarcik
		Edward D. Bednarcik.
		Chief Executive Officer and Director
		(Principal Executive, Financial and Accounting Officer)

25

Exhibit Index

EXHIBIT NUMBER	DESCRIPTION
3.1	Amended and Restated Certificate of Incorporation of Lighting Science Group Corporation (previously filed as Exhibit 3.1 to the Annual Report on Form 10-K filed on March 31, 2015, File No. 0-20354, and incorporated herein by reference).
3.2	Amended and Restated Bylaws of Lighting Science Group Corporation (previously filed as Exhibit 3.1 to the Current Report on Form 8-K filed on December 28, 2010, File No. 0-20354, and incorporated herein by reference).
3.3	Certificate of Amendment to Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.3 to the Annual Report on Form 10-K filed on March 31, 2015, File No. 0-20354, and incorporated herein by reference).
4.1	Specimen Common Stock Certificate (previously filed as Exhibit 4.14 to Amendment No. 1 to the Registration Statement on Form S-1/A filed on January 12, 2010, File No. 333-162966, and incorporated herein by reference).
4.2	Amended and Restated Certificate of Designation of Series H Convertible Preferred Stock filed with the Secretary of State of Delaware on November 14, 2014 (previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed on November 20, 2014, File No. 0-20354, and incorporated herein by reference).
4.3	Amended and Restated Certificate of Designation of Series I Convertible Preferred Stock filed with the Secretary of State of Delaware on November 14, 2014 (previously filed as Exhibit 4.2 to the Current Report on Form 8-K filed on November 20, 2014, File No. 0-20354, and incorporated herein by reference).
4.4	Amended and Restated Certificate of Designation of Series J Convertible Preferred Stock filed with the Secretary of State of Delaware on November 14, 2014 (previously filed as Exhibit 4.3 to the Current Report on Form 8-K filed on November 20, 2014, File No. 0-20354, and incorporated herein by reference).
4.5	Warrant Agreement, dated as of December 22, 2010, by and between Lighting Science Group Corporation and American Stock Transfer & Trust Company, LLC (previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed on January 4, 2011, File No. 0-20354, and incorporated herein by reference).
4.6	Warrant to Purchase Common Stock of Lighting Science Group Corporation, dated January 13, 2011 and issued to The Home Depot, Inc. (previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed on January 20, 2011, File No. 0-20354, and incorporated herein by reference).

26

EXHIBIT NUMBER	DESCRIPTION
4.7	Form of Warrant to Purchase Common Stock of Lighting Science Group Corporation, dated June 15, 2012 and issued to RW LSG Management Holdings LLC and certain other investors (previously filed as Exhibit 4.6 to Amendment No. 2 to the Registration Statement on Form S-1/A filed on September 27, 2012, File No. 333-172165, and incorporated herein by reference).
4.8	Warrant, dated as of September 25, 2012 and issued to Cleantech Europe II (A) LP (previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed on September 27, 2012, File No. 0-20354, and incorporated herein by reference).
4.9	Warrant, dated as of September 25, 2012 and issued to Cleantech Europe II (B) LP (previously filed as Exhibit 4.2 to the Current Report on Form 8-K filed on September 27, 2012, File No. 0-20354, and incorporated herein by reference).
4.10	Warrant, dated as of September 25, 2012 and issued to Portman Limited (previously filed as Exhibit 4.3 to the Current Report on Form 8-K filed on September 27, 2012, File No. 0-20354, and incorporated herein by reference).
4.11	Warrant, dated as of September 11, 2013, by and between Lighting Science Group Corporation and LSGC Holdings II LLC (previously filed as Exhibit 4.4 to the Current Report on Form 8-K filed on September 13, 2013, File No. 0-20354, and incorporated herein by reference).
4.12	Warrant, dated as of January 3, 2014, by and between Lighting Science Group Corporation and LSGC Holdings II LLC (previously filed as Exhibit 4.4 to the Current Report on Form 8-K filed on January 8, 2014, File No. 0-20354, and incorporated herein by reference).
4.13	Warrant, dated as of January 3, 2014, by and between Lighting Science Group Corporation and PCA LSG Holdings LLC (previously filed as Exhibit 4.5 to the Current Report on Form 8-K filed on January 8, 2014, File No. 0-20354, and incorporated herein by reference).
4.14	Warrant, dated as of January 3, 2014, by and between Lighting Science Group Corporation and RW LSG Holdings LLC (previously filed as Exhibit 4.6 to the Current Report on Form 8-K filed on January 8, 2014, File No. 0-20354, and incorporated herein by reference).
4.15	Warrant, dated as of January 3, 2014, by and between Lighting Science Group Corporation and PCA LSG Holdings LLC (previously filed as Exhibit 4.7 to the Current Report on Form 8-K filed on January 8, 2014, File No. 0-20354, and incorporated herein by reference).
4.16	Warrant, dated as of January 3, 2014, by and between Lighting Science Group Corporation and LSGC Holdings II LLC (previously filed as Exhibit 4.8 to the Current Report on Form 8-K filed on January 8, 2014, File No. 0-20354, and incorporated herein by reference).

27

EXHIBIT NUMBER	DESCRIPTION
4.17	Warrant, dated as of January 3, 2014, by and between Lighting Science Group Corporation and RW LSG Holdings LLC (previously filed as Exhibit 4.9 to the Current Report on Form 8-K filed on January 8, 2014, File No. 0-20354, and incorporated herein by reference).
4.18	Warrant, dated as of February 19, 2014, by and between Lighting Science Group Corporation and Medley Capital Corporation (previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed on February 25, 2014, File No. 0-20354, and incorporated herein by reference).
4.19	Warrant, dated as of February 19, 2014, by and between Lighting Science Group Corporation and Medley Opportunity Fund II LP (previously filed as Exhibit 4.2 to the Current Report on Form 8-K filed on February 25, 2014, File No. 0-20354, and incorporated herein by reference).
4.20	Warrant, dated as of February 19, 2014, by and between Lighting Science Group Corporation and Pegasus Capital Partners IV, L.P. (previously filed as Exhibit 4.4 to the Current Report on Form 8-K filed on February 25, 2014, File No. 0-20354, and incorporated herein by reference).
4.21	Warrant, dated as of February 19, 2014, by and between Lighting Science Group Corporation and Pegasus Capital Partners V, L.P. (previously filed as Exhibit 4.5 to the Current Report on Form 8-K filed on February 25, 2014, File No. 0-20354, and incorporated herein by reference).
4.22	Amended and Restated Registration Rights Agreement, dated as of January 23, 2009, by and between Lighting Science Group Corporation and Pegasus Partners IV, L.P. (previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed on January 30, 2009, File No. 0-20354, and incorporated herein by reference).
4.22.1	Amendment to Amended and Restated Registration Rights Agreement, dated as of May 25, 2012, by and among Lighting Science Group Corporation, Pegasus Partners IV, L.P. and LSGC Holdings LLC (previously filed as Exhibit 10.5 to the Current Report on Form 8-K filed on June 1, 2012, File No. 0-20354, and incorporated herein by reference).
4.23	Registration Rights Agreement, dated January 14, 2011, between Lighting Science Group Corporation and The Home Depot, Inc. (previously filed as Exhibit 4.2 to the Current Report on Form 8-K filed on January 20, 2011, File No. 0-20354, and incorporated herein by reference).
4.24	Amended and Restated Registration Rights Agreement, dated as of September 25, 2012, by and among Lighting Science Group Corporation, RW LSG Holdings LLC, RW LSG Management Holdings LLC, Portman Limited, Cleantech Europe II (A) LP and Cleantech Europe II (B) LP (previously filed as Exhibit 10.6 to the Current Report on Form 8-K filed on September 27, 2012, File No. 0-20354, and incorporated herein by reference).

28

EXHIBIT NUMBER	DESCRIPTION
4.25	Registration Rights Agreement, dated February 19, 2014 by and between Lighting Science Group Corporation, Medley Capital Corporation and Medley Opportunity Fund II LP (previously filed as Exhibit 4.3 to the Current Report on Form 8-K filed on February 25, 2014, File No. 0-20354, and incorporated herein by reference).
4.26	Registration Rights Agreement, dated as of November 14, 2014 by and between Lighting Science Group Corporation, Serengeti Lycaon MM L.P. and Serengeti Opportunities MM L.P. (previously filed as Exhibit 10.2 to the Current Report on Form 8-K filed on November 20, 2014, File No. 0-20354, and incorporated herein by reference).
4.27	Voting Agreement, dated as of September 25, 2012, by and between Lighting Science Group Corporation and RW LSG Holdings LLC (previously filed as Exhibit 10.7 to the Current Report on Form 8-K filed on September 27, 2012, File No. 0-20354, and incorporated herein by reference).
4.28	Voting Agreement, dated as of September 25, 2012, by and among Lighting Science Group Corporation, Pegasus Capital Advisors, L.P. and LSGC Holdings II LLC (previously filed as Exhibit 10.8 to the Current Report on Form 8-K filed on September 27, 2012, File No. 0-20354, and incorporated herein by reference).
10.1	Limited Consent and Second Amendment to Term Loan Agreement dated January 30, 2015 by and among Lighting Science Group Corporation, Medley Capital Corporation and the lenders party thereto (previously filed as Exhibit 10.2 to the Current Report on Form 8-K filed on filed on February 5, 2015, File No. 0-20354, and incorporated herein by reference).
10.2	Loan and Security Agreement, dated April 25, 2014, by and between Lighting Science Group Corporation, Biological Illumination, LLC, FCC, LLC, d/b/a First Capital, in its capacity as agent, and various financial institutions (previously filed as Exhibit 10.1 to the Current Report on Form 8-K filed on filed on February 5, 2015, File No. 0-20354, and incorporated herein by reference).
10.3	Second Amendment to Loan and Security Agreement dated January 30, 2015 by and among Lighting Science Group Corporation, BioLogical Illumination, LLC, the financial institutions from time to time party thereto as lenders and FCC, LLC, d/b/a First Capital (previously filed as Exhibit 10.2 to the Current Report on Form 8-K filed on filed on February 5, 2015, File No. 0-20354, and incorporated herein by reference).
10.4	Side Letter in Respect of Series J Equity Issuance and Calculation of Fixed Charge Coverage Ratio dated January 30, 2015 by and among Lighting Science Group Corporation, BioLogical Illumination, LLC and FCC, LLC, d/b/a First Capital (previously filed as Exhibit 10.2 to the Current Report on Form 8-K filed on filed on February 5, 2015, File No. 0-20354, and incorporated herein by reference).

29

EXHIBIT NUMBER	DESCRIPTION
10.5	Series J Subscription Agreement, dated January 30, 2015, by and between Lighting Science Group Corporation and LSGC Holdings III LLC (previously filed as Exhibit 10.1 to the Current Report on Form 8-K filed on February 5, 2015, File No. 0-20354, and incorporated herein by reference).
31.1*	Certification of Principal Executive Officer and Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document.
101.SCH		XBRL Taxonomy Extension Schema Document.
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.

____________________

* Filed herewith.

30